Related Experiment Video

Updated: Aug 29, 2026

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

[Hyperhomocysteinemia and deep-vein thrombosis]

Ling Qiu1, Sheng-kai Yan, Yao-hong Song

  • 1Department of Laboratory Medicine, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae
|January 13, 2004
PubMed

Insights

Elevated plasma homocysteine (Hcy) is a risk factor for deep-vein thrombosis (DVT). The interaction between low folate levels and MTHFR genotype significantly increases DVT risk.

Area of Science:

  • Medical Science
  • Genetics
  • Hematology

Context:

  • Deep-vein thrombosis (DVT) is a significant vascular condition.
  • Hyperhomocysteinemia, a condition of elevated homocysteine levels, is implicated in thrombotic events.
  • The role of methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and folate status in DVT pathogenesis requires further elucidation.

Purpose:

  • To investigate the association between plasma homocysteine (Hcy) levels and deep-vein thrombosis (DVT).
  • To analyze the interplay of Hcy, folate, and MTHFR gene polymorphism in DVT patients.
  • To determine if MTHFR C677T genotype and folate levels are independent risk factors for DVT.

Summary:

  • Plasma Hcy levels were significantly higher in DVT patients compared to controls.
  • No significant difference in MTHFR C677T genotype frequencies or serum folate/vitamin B12 levels was observed between groups.
  • Hyperhomocysteinemia was identified as an independent risk factor for DVT, with a notable interaction between low folate and the MTHFR TT genotype increasing DVT risk.

Impact:

  • Findings suggest hyperhomocysteinemia is a key risk factor for DVT in the Han population.
  • Serum folate levels and MTHFR C677T genotype alone are not significant risk factors.
  • The interaction between folate status and MTHFR genotype significantly contributes to DVT risk, highlighting potential therapeutic targets.
Abstract

More Related Videos

Venous Thrombosis Assay in a Mouse Model of Cancer04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...